Who are Administration of probiotics's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "Metronidazole" and "Lactobacillus", Bacillus Clausii Multi ATB Resist, Estrogen + probiotics, Lactobacillus casei variety rhamnosus granules, Lactobacillus Species, Lactobacillus Rhamnosus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/administration-of-probiotics.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Administration of probiotics — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Administration of probiotics (Administration of probiotics) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology, Immunology.

phase 3 Probiotic Gastroenterology, Immunology Biologic Live · refreshed every 30 min

Target snapshot

Administration of probiotics (Administration of probiotics) — Hospital General Universitario Elche. Probiotics restore and maintain a healthy gut microbiota composition, enhancing intestinal barrier function and modulating immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Administration of probiotics TARGET	Administration of probiotics	Hospital General Universitario Elche	phase 3	Probiotic
"Metronidazole" and "Lactobacillus"	"Metronidazole" and "Lactobacillus"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination
Bacillus Clausii Multi ATB Resist	Bacillus Clausii Multi ATB Resist	Sanofi	marketed	Probiotic
Estrogen + probiotics	Estrogen + probiotics	University Hospital, Ghent	marketed	Combination therapy (hormone replacement + probiotic)
Lactobacillus casei variety rhamnosus granules	Lactobacillus casei variety rhamnosus granules	Seoul National University Hospital	marketed	Probiotic / Live biotherapeutic product
Lactobacillus Species	Lactobacillus Species	Vedic Lifesciences Pvt. Ltd.	marketed	Probiotic
Lactobacillus Rhamnosus	Lactobacillus Rhamnosus	Chang Gung Memorial Hospital	marketed	Live biotherapeutic / Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Administration of probiotics — Competitive Intelligence Brief. https://druglandscape.com/ci/administration-of-probiotics. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab